If you or someone you know suffers from severe allergic reactions, you understand the urgency of quick treatment. Traditionally, that meant using an injection of epinephrine. But now, there’s a new option in the UAE that could make the difference: nasal spray EURneffy.
It’s the first product for severe allergies approved for emergencies, offering a quicker and simpler option compared to injections. The solution was developed by Denmark-based ALK Abelló.
EURneffy is approved for adults and children aged four and older, with the dosage based on body weight to ensure the correct amount of medication. Its form allows for quicker administration of epinephrine, making it a highly effective option during allergic emergencies where timely intervention is critical.
The UAE has become the first country in the region to approve this invention.
In late 2025, the country also approved a new type of flu vaccine, which, like EURneffy, is available as a nasal spray, reflecting the country’s commitment to innovative healthcare solutions.
